WeVote

Bill

Bill

HB 216

Relating to the provision of an abortion-inducing drug.

89th Legislature, 2nd Called Session (2025) Introduced by Ellen Troxclair

Texas bill proposing regulations on medication abortion access, likely restricting drug provision through additional state requirements or provider limitations.

Referred to State Affairs
0
WeVote Research Nonpartisan
Bill Summary · HB 216

Legislative bill overview

HB 216 proposes regulations governing the provision of abortion-inducing drugs (medication abortion) in Texas. The bill, filed by Representative Ellen Troxclair, was introduced in the 2025 legislative session and referred to the State Affairs Committee. Without access to the full bill text, the specific provisions remain unclear, though Texas has historically pursued restrictive abortion policies.

Why this is important

Medication abortion represents approximately 50% of all abortions nationally and is a significant policy battleground. Texas already has some of the nation's strictest abortion laws, including a near-total ban with limited exceptions. Any regulation of abortion-inducing drugs would directly affect healthcare access, physician practice, and reproductive options for Texas residents.

Potential points of contention

  • Access vs. restriction trade-off: Additional regulations could further limit availability or impose burdensome requirements on patients and providers, versus arguments that such measures ensure safety standards
  • Federal-state jurisdiction conflict: Medication abortion involves FDA-approved drugs (mifepristone); state restrictions may conflict with federal regulatory authority and existing legal challenges
  • Healthcare provider burden: Requirements on physicians, pharmacies, or telehealth providers could create practical compliance challenges and physician shortages in reproductive healthcare

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.